A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
A method of data encryption for messages transmitted between two or more computing devices includes determining a current secret key that is shared between a first computing device and a second computing device, calculating a current message authentication code (MAC) based on the current secret key and the message, calculating a subsequent secret key based on the current secret key using a one-way pseudorandom function, calculating a subsequent MAC by aggregating the current MAC and a first preceding aggregate MAC, and encrypting the message using the subsequent MAC and the subsequent secret key.
H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system
3.
SYSTEM AND METHOD OF FINE-TUNING LARGE LANGUAGE MODELS USING DIFFERENTIAL PRIVACY
A system and method of fine-tuning a large language model including differential privacy includes pretraining a large language model using a non-private dataset to generate a pretrained output. The pretrained output is used as an input to a fine-tuning model. The pretrained output is fine-tuned using a private dataset to generate a differentially private large language model. A set of privacy parameters including a privacy budget and a failure probability are determined. A privacy analysis agent calculates a desired amount of privacy based on the privacy budget, and calculates a noise multiplier based on the desired amount of privacy. The pretrained model is transformed using the noise multiplier to add an amount of noise to the pretrained output. A randomized differentially private stochastic gradient descent model fine-tunes the transformed pretrained output by reparametrizing a weight matrix associated with each layer of the transformed pretrained output.
The present disclosure provides for a photocrosslinkable tissue bonding composition comprising: a poly(ethylene glycol) functionalized with at least one photocrosslinkable group, a hydroxy-modified chitosan, and a photochemically active dye. Further provided herein is a photocrosslinked tissue bonding composition comprising: a photochemically active dye and a functionalized poly(ethylene glycol). Also disclosed is a kit for treating a wound, comprising a poly(ethylene glycol) functionalized with at least one photocrosslinkable group, a hydroxy-modified chitosan, a photochemically active dye, and an applicator. Further provided is a method for producing a photocrosslinkable tissue bonding composition and a method for treating a wound.
A novel composition and method of enhancing wound healing and minimizing rejection of an implant is presented. The composition is a dry acellular mixture comprised of conditioned media from mesenchymal stem cells, a multifunctional protease inhibitor, and a tethering peptide that acts as a tether to keep the composition in contact with the targeted area. An antimicrobial fusion peptide may also be added to the composition.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventor
Hall, Maclean
Abate-Daga, Daniel
Abstract
Disclosed are novel adoptive cell therapies comprising engineered CD4+ T cells comprising novel T cell receptors and methods of their use in the treatment of cancer.
Methods and systems for pain assessment are disclosed. The methods and systems include: obtaining a trained first, second, and third artificial intelligence (AI) models; obtaining sensor data for each modality of multiple modalities for a sequence length; determining a latent feature space in the sequence length for each modality of the multiple modalities based on the first AI model and the sensor data for each modality; generating a common latent space based on the second AI model and the latent feature space of each modality of the multiple modalities; generating a reconstructed latent space for each modality of the multiple modalities based on the common latent space and the second AI model; and determining a pain indication and/or a level of intensity based on the third AI model. Other aspects, embodiments, and features are also claimed and described.
G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
8.
NOVEL CYCLIC GAMMA AAPEPTIDE PAN-CORONAVIRUS INHIBITOR AND METHOD OF TREATING CORONAVIRUS INFECTION
A novel compound and method of treating and preventing coronavirus infection in a patient is presented. Cyclic γ AApeptide pan-coronavirus inhibitors which bind to RBD and HR1 on the spike protein were found to exhibit high proteolytic enzyme stability and good oral bioavailability. In particular, compound S-20-1 effectively inhibited infection by pseudotyped and authentic SARS-CoV-2 and pseudotyped variants of concern (VOCs), including B.1.617.2 (Delta) and B.1.529 (Omicron), as well as MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-229E, and HCoV-NL63 as well as infection of a pseudotyped SARS-related coronavirus WIV1 (SARSr-CoV-WIV1) from bats.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A method of treating or preventing Alzheimer's disease or related dementias in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Brain gene expression profiles of severe COVID-19 patients show increased expression of several innate immune response genes and genes implicated in Alzheimer's disease pathogenesis. The gene expression signature includes genes involved in inflammation, protein folding/trafficking, complement activation, calcium homeostasis, and amyloid/tau processing. The gene expression signature is correlated with tau pathology, α-synuclein, and demyelination with neuroinflammation being increased in old versus young CoV-2 infected mice.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
11.
SIMULTANEOUS POLARIZED LIGHT VIEWING/IMAGING THROUGH A SPLIT POLARIZER
Described herein relates to a system and method of filtering a polarized light through at least a polarization orientation for simultaneous viewing. The polarizing light filter apparatus may comprise at least one light source and/or a split polarizer configured to provide the polarization orientation of incident light. Light source may be configured to emit the incident light toward a structure, such that the incident light may be reflected off the structure through the split polarizing comprising a first polarization orientation (e.g., parallel) and/or a second polarizing orientation (e.g., cross). The reflected light may travel through the split polarizer, providing a simultaneous view of the first polarization orientation and/or the second polarization orientation, in real-time. Moreover, the simultaneous view of the polarized light may allow for a more detailed visual experience as well as optimize the ability to determine which orientation of light best illuminates a feature of interest.
A novel method for preventing Alu-mediated interferon related pathologies and excessive Alu-mediated interferon production and inflammatory response is presented. Administration of LIN28B was found to reduce IFN production by binding to Alu RTs and shielding them from binding to dsRNA sensors thus preventing Alu-mediated IFN related pathologies such as viral infections.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
13.
ALU SINES OF THE MIR-498(46) CISTRON MEDIATE INTRINSIC INTERFERON AND ANTIVIRAL RESPONSE IN HUMAN PLACENTA
Described herein relates to novel methods for determining susceptibility for infection and/or disease (e.g., pregnancy complication and/or cancer), and/or predicting severity of infection and/or disease by measuring circulating Alu RNA by RT-PCR (e.g., circulating blood, serum, and/or plasma). Additionally, described herein relates to novel methods of treating infection and/or disease (e.g., pregnancy complication and/or cancer), via increasing immune response, optimizing vaccine delivery, via administering at least one Alu RNA into the subject.
Provided are methods of modulating inflammation, modulating cancer cell trafficking, modulating chemokine receptor heteromerization, or modulating activity of a chemokine receptor by administering to a subject in need thereof a therapeutically effective amount of a modulator of an adrenergic receptor and/or an arginine vasopressin receptor. Chemokine receptor modulators can also be administered to the subject. Additionally, disclosed are compositions comprising a modulator of an adrenergic receptor and/or an arginine vasopressin receptor, and at least one cytokine receptor modulator.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A novel method of treating cancer is presented. API transcriptionally regulates SHIP-1 expression via the suppression of miRNA-155, impacting anti-tumor immune responses in the bone marrow (BM) and TME of mice with PC. The inventors discovered that API reduced miRNA-155 in the PC milieu, which induced SHIP-1 expression. This promoted the restoration of myelopoiesis and increased anti-tumor immune responses in the TME of heterotopic, orthotopic and transgenic SHIP-1 knockout preclinical mouse models of PC. The results suggest that manipulating SHIP-1 through miR-155 can assist in augmenting anti-tumor immune responses and aid in the therapeutic intervention of PC. Further, administration of both API and an miR-155 inhibitor were found to act synergistically to treat pancreatic cancer.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A novel method of treating diseases characterized by high PAI-1 is presented. Administering a composition comprising a therapeutically effective amount of genistein was found to inhibit PAI-1 promotor activity and decrease PAI-1 levels to treat diseases such as asthma, which exhibit increased PAI-1 levels. Genotyping the patient can be performed prior to administration to detect a 4G/5G polymorphism as patients having a 4G genotype have better response to the genistein treatment. The composition may be comprised of a therapeutically effective amount of genistein derived naturally from soybeans or synthetically produced and optionally present in nanoparticle form.
C07D 311/08 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
17.
CLASSIFICATION OF GLOBAL CELL PROLIFERATION BASED ON DEEP LEARNING
A method for automatic classification is disclosed. The method includes: training a deep learning model with a first set of a plurality of local images of first cells of a first tissue with a low magnification equal to or less than 40x; inputting a runtime image including second cells of a second tissue corresponding to the first tissue with the low magnification equal to less than 40x in the deep learning model; and automatically classifying a total number of the runtime cells in the runtime image as a proliferation level based on an output of the trained deep learning model. Other aspects, embodiments, and features are also claimed and described.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
Inventor
Cai, Jianfeng
Huang, Bo
Yin, Jun
Zhou, Li
Liu, Ruochuan
Abstract
Novel cyclic γ-AA peptides and methods of use thereof in modulating E3 activity are presented. Each novel compound is comprised of four γ-AA building blocks. It was found that in particular, compound P6 activated E6AP to stimulate self-ubiquitination of E6AP and E6AP-catalyzed substrate ubiquitination as well as enhance the ubiquitination of E6AP substrates in the cell and accelerate their degradation.
Systems, methods, and apparatus for frequency domain diffuse correlation spectroscopy are provided. In some embodiments, the system comprises: an intensity modulated coherent light source; a photon counting detector; at least one hardware processor that is programmed to: cause the light source to emit light at a plurality of different intensity modulation frequencies toward a tissue sample; detect, for each of the plurality of different modulation frequencies, photon counts over a predetermined period of time; determine, for each of the plurality of modulation frequencies, a normalized intensity auto-correlation function; estimate a plurality of properties of the tissue sample using the plurality of intensity auto-correlation functions; and output at least one of the plurality of properties.
A method and a system for identifying authenticity of an electronic component is disclosed. The method may include obtaining chip data of an electronic component; extracting feature information of the chip data for reducing noise of the chip data; providing the feature information of the chip data to a trained deep learning model; and providing a user with an authenticity indication for the electronic component based on an output of the deep learning model. Other aspects, embodiments, and features are also claimed and described.
Approaches to producing modular electronic packages include modular arrangements that operate from DC up to 110 GHz and are presented using additive manufacturing such as 3D printing and laser-machining. A method includes assembling electrical circuits from circuit components positioned on modular substrate sections by identifying respective positions of selected components of the electrical circuits on an original substrate; mapping a cut path across the original substrate, wherein the cut path is determined by the respective positions of the selected components; cutting the original substrate along the cut path, wherein the cut path separates the selected components of the electrical circuits onto substrate pieces defining respective side portions; and mating the respective side portions of the respective substrate pieces with corresponding side portions of other substrate sections to assemble the electrical circuits across substrate junctions.
H01L 21/78 - Manufacture or treatment of devices consisting of a plurality of solid state components or integrated circuits formed in, or on, a common substrate with subsequent division of the substrate into plural individual devices
H05K 1/11 - Printed elements for providing electric connections to or between printed circuits
B23K 26/06 - Shaping the laser beam, e.g. by masks or multi-focusing
23.
COMPOSITIONS AND USES THEREOF FOR TREATMENT OF NEUROLOGICAL DISORDERS
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/88 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins
24.
STING Modulators, Compositions, and Methods of Use
The present disclosure is directed to compounds of Formula (I), or pharmaceutically acceptable salts thereof and compounds of Formula (II), or pharmaceutically acceptable salts thereof, that modulate stimulator of interferon genes (STING), compositions comprising such compounds, and methods of using same for the treatment of disorders such as cancer and autoimmune disease.
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
Provided are systems and methods for converting C1 substrates to products contain more than one carbon, without producing central metabolic building blocks as intermediate products. In an embodiment, system/method can include a biochemical pathway enabling an orthogonal platform for C1 utilization based on formyl-CoA elongation (FORCE) reactions. In an embodiment, the system/method can include acyloin condensations between formyl-CoA and carbonyl-containing molecules. In an embodiment, the system/method can include a reactions catalyzed by the enzyme 2-hydroxyacyl-CoA lyase (HACL).
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymes; General processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
This disclosure provides a new conceptual framework in which orthogonal, new-to-nature carbon and energy conversion pathways facilitate the synthesis of fuels and chemicals from carboxylic acid intermediates (CAis) driven by genetically altered microorganisms. This allows the CAi platform to generate diverse products at ≥100% carbon yield while retaining the established high product and energy efficiencies of fermentative metabolism. In another embodiment, a carboxylic acid platform for fuel and chemical production at high carbon and energy efficiency is also provided.
A novel vector, composition and method of treating a UBE3A deficiency disease is presented. A novel UBE3A vector construct was generated with an additional secretion sequence to allow the secretion from cells. This secreted only E6AP protein maintains its presence outside the cell and is capable of diffusing to greater distances to cover more of the brain and rescue disease pathology.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/00 - Drugs for disorders of the nervous system
C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
A three-dimensional (3D) printed simulator that simulates at least a portion of a body is provided. The simulator includes a first simulated organ made of a first material having a first set of physical parameters, a second simulated organ made of a second material having a second set of physical parameters, and a transition layer made of a third material having a third set of physical parameters provided between the first simulated organ and the second simulated organ. The transition layer defines an anatomical plane between the first and second simulated organs.
B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
B33Y 70/00 - Materials specially adapted for additive manufacturing
A nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a single or a combination of therapeutic agents, optionally encapsulated in a nanoparticle having a targeting moiety directed to the particular coronavirus. For CoV-2 infections, at least one therapeutic agent, such as the dual DPP4/ACE2 inhibitor sitagliptin, may optionally be encapsulated within a nanoparticle having a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A multi-functional broad-spectrum antiviral and anti-inflammatory nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a combination of therapeutic agents directed to the particular coronavirus encapsulated in a nanoparticle that is surface coated with a targeting moiety. For CoV-2 infections, an antiviral such as the PPAR-γ agonist leriglitazone (LG) and an siRNA targeting a conserved sequence of the virus can be encapsulated within a nanoparticle surface coated with a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.
A61K 31/4427 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
This disclosure relates to antimicrobial compositions, and more particularly to treatment of surfaces (e.g., face masks) for the reduction or prevention of transmission of microbes (e.g., bacteria, fungus, and/or viruses). In some embodiments, the compositions comprise a cationic polymer selected from the group consisting of: a polydiallyldimethylammonium salt, a polyethyleneimine salt, a polydiallyldimethylammonium with different counter ions, a chemically modified polyethyleneimine salt, or a combination thereof.
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventor
Muncy, Aaron
Enderling, Heiko
Pasetto, Stefano
Passaglia, Christopher
Yarinsky, Jacob
Pinto, Carolyna Yamamoto Alves
Blocker, Abby
Abstract
A ventilator device for co-ventilation of multiple patients may include an air tube splitter having an inlet, a plurality of outlets, and a plurality of branches each extending to a respective outlet, a plurality of valves coupled to the branches, a plurality of actuators coupled to the valves, and a controller in operable communication with the actuators. Each valve may be configured to be adjusted to regulate air flow through a respective branch. Each actuator may be configured to adjust a respective valve. The controller may be configured to receive a set of inspiratory pressure settings or tidal volume settings for the patients and independently control the actuators to adjust the valves based at least in part on the set of inspiratory pressure settings or tidal volume settings. The controller may employ time-multiplexing in controlling the actuators to adjust the valves for ventilating the patients at different times.
A61M 16/20 - Valves specially adapted to medical respiratory devices
A61M 99/00 - Subject matter not provided for in other groups of this subclass
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
34.
PEPTIDE-SMALL INTERFERING RNA-HYALURONIC ACID NANOPARTICLES AND METHODS OF USE THEREOF
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
35.
SYSTEMS AND METHODS FOR SOLAR THERMAL OSMOSIS DESALINATION
Disclosed herein is a solar thermal osmosis desalination system comprising a forward osmosis subsystem and a reverse osmosis subsystem where the forward osmosis subsystem is configured to receive solar thermal heat and generate power that can be used to operate the reverse osmosis subsystem.
Systems and methods for processing a service request within a network environment can include a first cluster of fog nodes that execute service tasks. The cluster can include a primary fog node and nearest neighbor fog nodes. The primary fog node can receive, from the network, a service request, determine service request resource data that includes a first time, quantity of resource blocks required to serve the request, and a hold time required to serve the request locally. An edge controller, connected to the network and the first cluster, can receive, from the primary fog node, the service request resource data, identify available resources at the nearest neighbor fog nodes and the primary fog node, and determine whether resource blocks are available to fulfill the service request using deep reinforcement learning algorithms. The edge controller can also refer a rejected service request to a cloud computing system for execution.
Images of an insect larva are subjected to at least a first convolutional neural network to develop feature maps based on anatomical pixels at corresponding image locations in the respective feature maps. The anatomical pixels correspond to a body part of the insect larva. A computer uses a plurality of feature maps form an integrated feature map and bounding boxes on anatomical pixels corresponding to a head, thorax, abdomen, or terminal abdomen area of the insect larva. A classification network identifies the genus, the species, the sex, or the life stage of the insect larva.
ynthetic ynthetic Multi-Exposure Speckle Imaging (syMESI), in which with the use of conventional, conventionally substantially incapable of quantitative assessment of a motion (at a scene being imaged) LSCI apparatus, such quantitative results are obtained with the use of empirical imaging at only one, fixed-duration exposure time and the following transformation of the so-obtained raw speckle image(s) with the use of various spatial averaging to obtain speckle images representing multiple different synthetic exposure times and, optionally – speckle contrast images.
In some implementation, a system for identifying malicious attacks on a convolutional neural network (CNN) model includes a target computing system that performs classification of objects using a CNN model, and an attack identification computing system that identifies an injected neural attack. The attack identification computing system can be configured to generate, based on the CNN model and associated parameters, an ecosystem of CNN models by modifying original weights of the parameters associated with the CNN model; update the original weights of the parameters with the modified weights; store, in a secure data store, the updated weights of the parameters; generate, based on the updated weights, an update file for the CNN model; update, using the update file, the CNN model; and transmit the updated CNN model to a targeting computing system configured to detect neural attacks by an attacker computing system based on the updated CNN model.
In one embodiment, an authentication scheme (500) that combines chaotic antenna array geometries with pseudorandom pilot sequences and antenna array activation sequences is provided. A receiving device (110A) receives a pilot signal (130) from a transmitting device (110B) (501). The receiving device computes a unique signature (125) for the transmitting device that captures differences between the received signal and expected pilot signal (503). The differences may be due to a unique antenna array geometry of the transmitting device, a pseudorandom pilot sequence used by the transmitting device, and an antenna array activation sequence used by the transmitting device. Later, this computed unique signature may be used by other receiving devices to authenticate the transmitting device (505; 507).
Structures of a particle containing a core and at least one shell, a metal oxide material of which is necessarily doped to ensure protection of a material of the core from photodegradation. The core can include any of a thermochromic material, a phase-change material, and a judiciously defined auxiliary material that in turn contains organic and/or polymeric material. Derivative products utilizing a plurality of such particles. Methodologies for producing such particles and derivative products.
A dispensing system can include a container including multiple channels, and each channel can be capable of containing an amount of a liquid. The dispensing system can include a well plate including multiple wells, and each well can be configured to align with a respective channel of the container. The dispensing system can include a plunger including multiple protrusions, and each protrusion can be configured to be inserted into a respective channel of the container. Movement of the plunger toward the container can force each protrusion to be inserted into the respective channel of the container thereby driving liquid from the respective channel and into a respective well of the well plate.
A system and method for pain level recognition using an automated approach which incorporates a pain-affect dataset comprising bioVid pain and bioVid emotion datasets for the assessment of patient pain in clinical settings where patients often experience other affect states, such as anger and anxiety, in addition to pain.
Disclosed are devices and methods for synthesizing products. The disclosed devices and methods may be used to synthesize products, e.g., pharmaceutical or therapeutic compounds (i.e., drugs), ceramics, catalysts, biological polymers (i.e., proteins, enzymes), cells, tissues, or combinations thereof. The devices and methods may be operated in a microgravity environment.
B01J 2/20 - Processes or devices for granulating materials, in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by expressing the material, e.g. through sieves and fragmenting the extruded length
B01J 2/10 - Processes or devices for granulating materials, in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
Disclosed herein are electrotransfer (ET) methods for delivering therapeutic agents to tumors. Also disclosed are methods of using the ET methods for differential delivery of an agent to more than one tissue. For example, the ET methods can be used to deliver soluble peptides of PD1 to tumor tissue to block normal PD1-PDL1 binding while separately using the ET methods to deliver PD1 or PDL1 antigen to another tissue, such as skin or muscle, to induce systemic and polyclonal checkpoint inhibitor antibodies.
A method of treating a sacroiliac joint and/or a region proximate the sacroiliac joint includes distracting and/or stabilizing a recess between a sacral wall of a sacrum and an ilial wall of an ilium, cutting a surface of the ilial wall using a cutting device, and positioning an implant having a first planar wall and a second planar wall opposite the first planar wall into the recess, such that the first planar wall of the implant is in contact with an uncut surface of the sacral wall, and the second planar wall is in contact with the cut surface of the ilial wall. The implant can be formed as a wedge-shape, a double-wedge shape, or a cuboid shape.
A method of preventing asthma is presented. A therapeutically effective amount of at least one soy isoflavone is administered to those patients exhibiting a PAI-1 risk genotype of 4G4G or 4G5G. The administration of the at least one soy isoflavone prevents development of asthma in the patients, particularly in pediatric patients which have suffered a viral illness within the first few years of life. Administration of the soy isoflavones to those pediatric patients throughout the viral season is beneficial in preventing the development of asthma.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 11/00 - Drugs for disorders of the respiratory system
A soft ferrite composition comprises a ferrimagnetic ceramic material having a crystal structure and a dopant in the crystal structure, wherein the ceramic material comprises an oxide including nickel, cobalt, zinc, and iron, wherein the dopant is selected from the group consisting of copper oxides, and wherein the dopant is present in the crystal structure at 0.1 to 20 weight percent based on a total weight of the composition. The dopant can be CuO. The copper oxide doped Ni-Co-Zn ferrite can be used for very high frequency (VHF) and ultra high frequency (UHF) applications such antennas, isolators, and circulators.
C04B 35/26 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on ferrites
49.
SYSTEMS AND METHODS FOR ENERGY EFFICIENT AND USEFUL BLOCKCHAIN PROOF OF WORK
The disclosure provides systems and methods for an improved Proof of Work (PoW) technique that enforces the creation of cryptographic tokens while solving the PoW puzzle. The systems and methods disclosed herein more efficiently utilize the high computational and energy consumption in attempts to solve PoW puzzles, by combining the computations necessary for several types of cryptographic functions (e.g., public-key cryptographic methods). For example, systems and methods disclosed herein may reuse pre-computed commitments, while still preserving the traditional and accepted PoW protocols.
H04L 29/06 - Communication control; Communication processing characterised by a protocol
H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system
G06F 21/64 - Protecting data integrity, e.g. using checksums, certificates or signatures
50.
SYSTEMS AND METHODS FOR PREDICTIVE SAFETY ASSESSMENT
A method for generating a predictive safety assessment of at least one existing facility and at least one proposed facility includes obtaining data about an existing facility and each proposed facility, receiving user input data regarding local conditions for the existing facility and each proposed facility, determining a predicted crash frequency for the existing facility and each proposed facility based at least on a set of Safety Performance Function (SPFs) associated with a facility type for the existing facility and each proposed facility respectively, determining a conversion factor for each proposed facility based on the predicted crash frequency of the existing facility and the predicted crash frequency of each proposed facility, determining a crash severity distribution by crash types, determining an impact of local traffic volume for each proposed facility, and generating a user interface to render a graphical representation of at least each conversion factor for each proposed facility.
A method analyzing benefits and cost for a roadway improvement project includes obtaining definitions of a plurality of emphasis areas associated with a highway safety plan, and obtaining crash data associated with each of the plurality of emphasis areas. The crash data can include a plurality of crashes, a location of each crash, functional class associated with each crash, and injury levels associated with each crash. The method further includes obtaining countermeasure and Crash Modification Factor (CMF) data associated with each emphasis area, obtaining spatial assignments for each crash, determining a frequency of crashes for at least one injury level for each emphasis area, determining a plurality of costs associated with each countermeasure in the countermeasure and CMF data, a benefit cost ratio for each countermeasure in the countermeasure and CMF data associated with the emphasis area, and generating a first user interface configured to render a table or a visualization based at least on at least one emphasis area, the set of countermeasures, and the benefit cost ratio associated with the at least one countermeasure.
An insect trap includes a combination of one or more components used to classify the insect according to a genus and species. The trap includes an imaging device, a digital microphone, and passive infrared sensors at the entrance of the trap to sense wing-beat frequencies and size of the insect (to identify entry of a mosquito). A lamb-skin membrane, filled with an insect attractant such as carbon dioxide mixed with gas air inside, mimics human skin so that the insect can rest on the membrane and even pierce the membrane as if a blood meal is available. An imaging device such as a passive infrared sensor or a camera gathers image data of the insect. The insect may be a mosquito.
A system configured to perform the DCS-type measurements with the use of low-coherence continuous-wave (CW) light source at levels of light intensities that are substantially lower and with pathlengths through the tissue that are substantially longer than those afforded by the use of conventional methods. The method includes utilizing the optical detection system to producing signals representing interference between the portion of CW light arriving through reference arm of interferometer and the sample CW light potion that has traversed the sample arm including different paths through the target tissue while switching between first and second of said different paths only by adjusting a delay in the delay line. The spatial resolution of different pathlengths of sample light through tissue is defined by coherence length of CW light.
Provided herein are systems and methods for automated identification of volumes of interest in volumetric brain images using artificial intelligence (AI) enhanced imaging to diagnose and treat acute stroke. The methods can include receiving image data of a brain having header data and voxel values that represent an interruption in blood supply of the brain when imaged, extracting the header data from the image data, populating an array of cells with the voxel values, applying a segmenting analysis to the array to generate a segmented array, applying a morphological neighborhood analysis to the segmented array to generate a features relationship array, where the features relationship array includes features of interest in the brain indicative of stroke, identifying three-dimensional (3D) connected volumes of interest in the features relationship array, and generating output, for display at a user device, indicating the identified 3D volumes of interest.
A battery management system comprises: a circuit path electrically coupling a battery and a load; a backup storage device; a first switch connecting the battery and the backup storage device; a second switch connecting the backup storage device and the load; a sensor for measuring a temperature of the battery; and a controller in electrical communication with the first switch, the second switch, and the sensor. The controller executes a program to: (i) activate the first switch to connect the battery and the backup storage device for charging the backup storage device for a charging period of time with power provided by the battery based on the temperature of the battery meeting a threshold, and (ii) activate the second switch to connect the backup storage device and the load for providing power to the load from the backup storage device after the charging period of time has expired.
H01M 10/633 - Control systems - characterised by algorithms, flow charts, software details or the like
H01M 10/635 - Control systems based on ambient temperature
H01M 10/65 - Means for temperature control structurally associated with the cells
H01M 10/651 - Means for temperature control structurally associated with the cells characterised by parameters specified by a numeric value or mathematical formula, e.g. ratios, sizes or concentrations
22, CO, formaldehyde, methanol, and methane, for growth and instead prefer complex feedstocks such as sugars. Disclosed herein is a system that enables organisms to consume one carbon molecules for growth and maintenance via a formyl-CoA elongation pathway. Utilization of one carbon feedstocks can replace the use of sugar as the primary means of cultivating organisms in biotechnological applications. This has the potential to be more cost effective and avoid the controversial use of food as feedstocks. Intermediates of the formyl-CoA elongation pathway may be also be converted to desired chemical products.
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymes; General processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
57.
WATER-BASED-ORGANIC ELECTROLYTE ELECTROCHROMIC DEVICES WITH LOWER POWER CONSUMPTION AND IMPROVED CYCLABILITY
The use of materially-asymmetric electrodes in an electro-chromic (EC) cell having a single active layer that employs a water-based gel electrolytic material solves a problem that is exhibited during operation of conventionally-structured devices and that is caused by electrolysis of water in the gel and formation of gas bubbles inside the conventionally-structured devices, thereby substantially increasing the number of operational cycles such devices can be subjected to.
G02F 1/1523 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising inorganic material
G02F 1/15 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect
58.
CANNABINOID COMPOSITIONS AND DOSAGE FORMS FOR INTRANASAL OR INHALATIONAL DELIVERY
The present invention provides pharmaceutical compositions and methods for use and manufacture thereof. The pharmaceutical compositions comprise a therapeutically effective amount of a cannabinoid or a pharmaceutically acceptable salt or solvate thereof and an amphiphilic copolymer comprising at least one hydrophilic component and at least one hydrophobic component. The cannabinoid is encapsulated in the amphiphilic copolymer, and the composition is suitable for intranasal or inhalation delivery.
A61K 9/22 - Sustained or differential release type
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
The invention relates to a non-contact printing method and system as well as to a printed sensor. The method includes the steps of disposing a substrate (130) between a discharge electrode (110) and a printing material (140) such that the substrate (130) is spaced apart from the printing material (140); and activating the discharge electrode (110) to generate an electric field between the substrate (130) and the printing material (140), wherein the printing material (140) moves onto a surface (132) of the substrate (130) when the electric field attracts the printing material (140) to the surface (132) of the substrate (130). A corresponding printing system and printed sensor are also provided.
G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
60.
DETERMINING ELECTRONIC COMPONENT AUTHENTICITY VIA ELECTRONIC SIGNAL SIGNATURE MEASUREMENT
Examples of determining electronic component authenticity via electronic signal signature measurement are discussed. Reference pin identifiers corresponding to pins of a known authentic electronic component are determined. Measurement values corresponding to characteristics of pins of an electronic component are obtained, and pin identifiers based on the measurement values are generated. Accordingly, an indication that the electronic component is authentic can be provided based at least in part on a comparison of the pin identifiers and the reference pin identifiers.
G06F 21/00 - Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
H04L 9/00 - Arrangements for secret or secure communications; Network security protocols
G06F 12/14 - Protection against unauthorised use of memory
G06F 12/00 - Accessing, addressing or allocating within memory systems or architectures
H04L 9/06 - Arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
61.
METHOD OF MAKING LECTURES MORE INTERACTIVE WITH REALTIME AND SAVED QUESTIONS AND ANSWERS
Disclosed are various embodiments of a module publication application, interactive modules, and student user interfaces that make lectures more interactive. An instructor user interface generated by the module publication application captures a video of a lecture. Interactive modules including video segments and segment metadata are generated based on the video. A student user interface can render a presentation of the video segments and an interactive region showing questions that are related to the presentation. The questions shown in the interactive region can be updated based on a current timecode of the presentation.
G09B 7/08 - Electrically-operated teaching apparatus or devices working with questions and answers of the multiple-choice answer type, i.e. where a given question is provided with a series of answers and a choice has to be made from the answers characterised by modifying the teaching programme in response to a wrong answer, e.g. repeating the question, supplying further information
G09B 5/06 - Electrically-operated educational appliances with both visual and audible presentation of the material to be studied
G09B 5/12 - Electrically-operated educational appliances providing for individual presentation of information to a plurality of student stations different stations being capable of presenting different information simultaneously
G09B 7/02 - Electrically-operated teaching apparatus or devices working with questions and answers of the type wherein the student is expected to construct an answer to the question which is presented or wherein the machine gives an answer to the question presented by the student
G09B 7/07 - Electrically-operated teaching apparatus or devices working with questions and answers of the multiple-choice answer type, i.e. where a given question is provided with a series of answers and a choice has to be made from the answers providing for individual presentation of questions to a plurality of student stations
An intraocular optic capture device is provided to replace an intraocular lens dislocated within an eye. The intraocular optic capture device includes a body defining an opening configured to receive and hold the intraocular lens. The intraocular optic capture device includes one or more fixing arms extending from the body and configured to fix the body to a structure of the eye.
A61F 9/00 - Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
A three-dimensional printed swab may include a shaft defining a longitudinal axis of the swab, and a tip portion integrally formed with the shaft. The tip portion may include a plurality of protrusions each extending outward from the shaft and transverse to the longitudinal axis. A method for fabricating a three-dimensional printed swab may include receiving a digital three-dimensional model corresponding to the swab, and integrally forming, via three-dimensional printing and based at least in part on the digital three-dimensional model, a shaft and a tip portion of the swab. The shaft may define a longitudinal axis of the swab. The tip portion may include a plurality of protrusions each extending outward from the shaft and transverse to the longitudinal axis.
The present disclosure is directed to methods for the treatment of inflammation or pain, particularly methods using compositions containing a compound of formula (I).
A breathing system for removing harmful contaminants, such as microbes and volatile organic compounds, is provided. The breathing system includes a face mask, an inhalation limb, and a plasmonic device. As a contaminated gas flows through an internal chamber of the plasmonic device, the contaminates are oxidized. Specifically, the internal chamber includes a source of photons spaced apart from the nanostructure. The nanostructure is coated in a plasmonic layer, including noble metal nanoparticles. The plasmonic layer is protected from oxidation through a photocatalyst layer disposed thereon.
A62B 7/10 - Respiratory apparatus with filter elements
A62B 23/02 - Filters for breathing-protection purposes for respirators
B01D 53/00 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols
66.
INHIBITION OF BETA-ARRESTIN OLIGOMERIZATION IN TAUOPATHY
As disclosed herein, β-arrestin1 and β-arrestin2 levels are highly elevated in brains of FTLD-tau patients suggesting that both β-arrestin1 and β-arrestin2 are elevated in the brains of patients with AD and FLTD. The current work also shows that when β-arrestin2 is overexpressed, tau levels become elevated. The data indicate that β-arrestin2 reduces tau clearance by impairing p62-mediated autophagy, a role carried out by the oligomerized form of β-arrestin2. Therefore, disclosed herein are β-arrestin oligomerization inhibitors that can be used to prevent β-arrestin oligomerization and therefore the accumulation of tau in cells, i.e. tauopathy. Also disclosed are methods of treating a tauopathy in a subject that involve administering to the subject a therapeutically effective amount of a β-arrestin oligomerization inhibitor disclosed herein.
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
68.
INTEGRATED DETECTION SCHEME FOR FAST BLOOD FLOW MEASUREMENT
Disclosed are various embodiments for an integrated detection scheme for fast blood flow measurement. A first control signal can be sent to a switch to cause an integrator to integrate a current from a photodiode. An integrated current can be received from the integrator, and a data signal can be sent to a computing device based at least in part on the integrated current. A second control signal can be sent to a switch to cause the integrator to cease integrating the current from the photodiode.
FMR1FMR1FMR1-/-FMR1-/- mice as evaluated in the Hidden Platform Water Maze, Open Field and Fear Conditioning. Reelin gene therapy is therefore potentially a novel therapeutic for the treatment of Fragile X Syndrome.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
70.
COVALENT ORGANIC FRAMEWORKS AND APPLICATIONS AS PHOTOCATALYSTS
Described herein are covalent organic frameworks. The covalent organic frameworks have unique structural and physical properties, which lends them to be versatile in a number of different applications and uses. In one aspect, the covalent organic frameworks are composed of a plurality of fused aromatic groups and electron-deficient chromophores. The covalent organic frameworks are useful as photocatalysts in a number of different applications.
B01J 31/12 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides
B01J 35/10 - Solids characterised by their surface properties or porosity
C07C 27/16 - Processes involving the simultaneous production of more than one class of oxygen-containing compounds by oxidation of hydrocarbons with other oxidising agents
71.
SYSTEMS AND METHODS OF DEEP LEARNING FOR COLORECTAL POLYP SCREENING
Disclosed are various embodiments of systems and methods of deep learning for colorectal polyp screening and providing a prediction of neoplasticity of a polyp. A video of a colonoscopy procedure can be captured. Frames from the video or images associated with the colonoscopy procedure can be extracted. A model for classifying objects that appear in the frames or the images can be obtained. A classification can be determined for a polyp that appears in at least one of the frames or images based on applying the frames or images to an input layer of the model.
Provided herein are systems and methods for sampling analytes into an atmospheric pressure inlet mass spectrometer using ultrasonic nebulization-assisted atmospheric pressure chemical ionization. The systems can include a mass spectrometer having an input and an ultrasonic nebulizer chip. The ultrasonic nebulizer chip can be operatively coupled to the mass spectrometer, such that when the ultrasonic nebulizer chip nebulizes the analyte to provide a nebulized analyte, at least some of the nebulized analyte enters the input of the mass spectrometer.
B05B 17/06 - Apparatus for spraying or atomising liquids or other fluent materials, not covered by any other group of this subclass operating with special methods using ultrasonic vibrations
UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventor
Peterson, Matthew, J.
Cowan, Linda, J.
Hall, Kimberly, S.
Goldgof, Dmitry
Sarkar, Sudeep
Pai, Chih-Yun
Morera, Hunter
Sun, Yu
Abstract
Methods and systems for imaging and analysis are described. Accurate pressure ulcer measurement is critical in assessing the effectiveness of treatment. However, the traditional measuring process is subjective. Each health care provider may measure the same wound differently, especially related to the depth of the wound. Even the same health care provider may obtain inconsistent measurements when measuring the same wound at different times. Also, the measuring process requires frequent contact with the wound, which increases risk of contamination or infection and can be uncomfortable for the patient. The present application describes a new automatic pressure ulcer monitoring system (PrUMS), which uses a tablet connected to a 3D scanner, to provide an objective, consistent, non-contact measurement method. The present disclosure combines color segmentation on 2D images and 3D surface gradients to automatically segment the wound region for advanced wound measurements.
Compositions and methods of treatment for inhibiting capillary tube regression and/or lymphatic tube regression are described, as well as factors and signaling pathways that control the regression of capillary tube networks. Capillary tube regression and/or lymphatic tube regression may be implicated in ischemia, infarction, hypertension, diabetes, malignant cancer, neurodegenerative disease, wound repair response, atherosclerosis, pro-inflammatory disease, pro-thrombotic disease, viral infection (e.g., influenza or SARS-CoV-2), bacterial infection.
The present application is directed to pharmaceutical combinations comprising mithramycin and immunotherapy to target cancer initiating stem cells (CSCs). The present application also discloses methods of treating cancer comprising administering mithramycin and immunotherapy to a subject in need thereof.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
C07H 15/24 - Condensed ring systems having three or more rings
76.
DIODE-PUMPED MULTIPASS CAVITY RAMAN GAS SENSOR AND METHOD OF USE
A method for enhancement of spontaneous Raman scattering (SRS) from gases comprising a multimode blue laser diode which receives feedback from a near concentric bidirectional multipass cavity in such a way as to generate a circulating power of order 100 W for a sample volume of 10 mm3. The feedback, provided via a volume Bragg grating, reduces the laser bandwidth to 4 cm-1. Spectra of spontaneous Raman scattering from ambient atmospheric air, detected collinearly with the pump, were recorded with a limit of detection below 1 part-per-million.
An exemplary hybrid solar cell device comprises a photovoltaic solar cell having a positive terminal and a negative terminal and a thermoelectric module unit having a positive terminal and a negative terminal, wherein the thermoelectric module unit comprises at least one thermoelectric module. Such a hybrid solar cell device has a hot side of the thermoelectric module oriented towards an external heat source; the positive terminal of the photovoltaic solar cell connected in series with the negative terminal of the thermoelectric module unit, and a load connected between the positive terminal of the thermoelectric module and the negative terminal of the photovoltaic solar cell.
H01L 35/30 - SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR - Details thereof operating with Peltier or Seebeck effect only characterised by the heat-exchanging means at the junction
H01L 21/00 - Processes or apparatus specially adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
H01L 35/28 - SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR - Details thereof operating with Peltier or Seebeck effect only
H01L 35/32 - SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR - Details thereof operating with Peltier or Seebeck effect only characterised by the structure or configuration of the cell or thermocouple forming the device
H01L 35/34 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
H02J 3/14 - Circuit arrangements for ac mains or ac distribution networks for adjusting voltage in ac networks by changing a characteristic of the network load by switching loads on to, or off from, network, e.g. progressively balanced loading
78.
SYSTEMS AND METHODS TO OPTIMIZE AND FRACTIONIZE RADIATION FOR PERSONALIZED RADIATION THERAPY
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventor
Torres-Roca, Javier
Peacock, Jeffrey
Liu, Xiaoming
Abstract
Systems and methods for personalized dose and fractionation for radiation therapy are described herein. An example method can include predicting a patient-specific radiosensitivity parameter alpha (α) value for a tumor, where the patient-specific radiosensitivity parameter alpha (α) value is predicted based on a first set of signature genes. The method can also include predicting a patient-specific radiosensitivity parameter beta (β) value for the tumor, where the patient-specific radiosensitivity parameter beta (β) value is predicted based on a second set of signature genes. The method can further include calculating a patient-specific dose and fractionation using a radiation cytotoxicity score (RCS) function and the patient-specific radiosensitivity parameters alpha (α) and beta (β) values. RCS is predictive of clinical outcome.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
79.
STING MODULATORS, COMPOSITIONS, AND METHODS OF USE
The present disclosure is directed to compounds of Formula (I), or pharmaceutically acceptable salts thereof and compounds of Formula (II), or pharmaceutically acceptable salts thereof, that modulate stimulator of interferon genes (STING), compositions comprising such compounds, and methods of using same for the treatment of disorders such as cancer and autoimmune disease.
Described herein are composite materials composed of ceramic particles coated with a surfactant incorporated within a polymer matrix, methods of making same, filaments composed of the same, and articles printed using the filaments. The composite materials and articles described herein have desirable electronic and thermal properties for use in radio frequency (RF) and millimeter wave devices and demonstrate reliable performance at elevated humidity levels.
H01B 1/22 - Conductive material dispersed in non-conductive organic material the conductive material comprising metals or alloys
H01B 1/24 - Conductive material dispersed in non-conductive organic material the conductive material comprising carbon-silicon compounds, carbon, or silicon
C08K 3/013 - Fillers, pigments or reinforcing additives
81.
SYSTEM AND METHOD FOR IMAGING TENDON CROSS SECTIONS FOR DETECTING VOIDS AND OTHER DEFICIENCIES IN GROUTED EXTERNAL TENDONS
An exemplary method of indicating a condition of grout within a post-tensioned tendon involves positioning a magnet and a metallic sensing plate in close proximity to an outer surface of the post-tensioned tendon; rotating the magnet and the metallic sensing plate around the outer surface of the post-tensioned tendon; measuring an amount of magnetic forces applied to the magnet during rotation of the magnet around the post-tensioned tendon; measuring an impedance between the metallic sensing plate and metallic strands within the post-tensioned tendon during rotation of the metallic sensing plate around the post-tensioned tendon; and generating an image of a cross-section of the post-tensioned tendon indicating one or more grout conditions in spatial proximity to the metallic strands within the post-tensioned tendon based on measurement data using the magnet and the metallic sensing plate.
G01V 3/08 - Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination or deviation operating with magnetic or electric fields produced or modified by objects or geological structures or by detecting devices
E04C 5/08 - Members specially adapted to be used in prestressed constructions
82.
COMPOSITIONS AND METHODS FOR TREATING ALZHEIMERS DISEASE
The present application relates to compositions comprising (i) THC; (ii) melatonin; and (iii) insulin and methods of using same to Alzheimer's disease in a subject in need thereof without the psychological impairment and side effects associated with THC.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Described herein are compositions composed of frustrated Lewis pairs impregnated in porous materials such as, for example, metal-organic frameworks, and their uses thereof. These compositions may allow new applications of frustrated Lewis pairs in catalysis by sequestering and protecting the frustrated Lewis pair within the nanospace of the porous material. Also provided are methods of hydrogenating an organic compound having at least one unsaturated functional group comprising using the compositions described herein.
B01J 31/18 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony
C07C 5/03 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by hydrogenation of non-aromatic carbon-to-carbon double bonds
C07C 37/07 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by conversion of non-aromatic six-membered rings or of such rings formed in situ into aromatic six-membered rings, e.g. by dehydrogenation with simultaneous reduction of C=O group in that ring
84.
METHODS FOR TREATING CANCER USING X-RAY-INDUCED NEAR INFRARED PHOTOIMMUNOTHERAPY
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
85.
CHITOSAN BASED MEMBRANE AND ASSOCIATED METHOD OF USE
A membrane comprising chitosan for use in Reverse Osmosis (RO) desalination, or for extracting economically valuable materials from seawater or another highly saline industrial fluid using a thin film composite (TFC) membrane porous support layer comprising chitosan, or for reducing the saline content of one or more industrial or mining fluids for hazardous waste disposal in operations such as desalinization or hydraulic fracturing fracking using a thin film composite (TFC) membrane porous support layer comprising chitosan. The chitosan-based membrane may also be used as part of a dialytic membrane electrode assembly for use in the generation and storing of low across membrane voltages and currents across a salinity concentration gradient.
Compositions and methods for treating traumatic brain injury (TBI) are presented. Novel dendriplexes are formed from poly(amidoamine) (PAMAM) dendrimers complexed with shRNA encoding DNA plasmids encapsulating shRNA encoding chemokine ligand 20 (CCL20) gene, chemokine receptor 6 (CCR6) gene, or a combination thereof. The dendriplexes are dually administered, both intranasally and intravenously, prior to administration of stem cells, such as human mesenchymal stem cells (hMSCs) for the treatment of traumatic brain injury (TBI). Administration of the dendriplexes prior to stem cell administration resulted in a decrease in neurodegeneration, neuroinflammation, microgliosis and astrogliosis. In addition, a synergistic increase in brain derived trophic factor (BDNF) was shown by administration of the combination of dendriplex and stem cell administration.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (USA)
Inventor
Cai, Jianfeng
Sang, Peng
Shi, Yan
Ji, Haitao
Zhang, Min
Abstract
Disclosed herein is a series of helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9, and selectively disrupt β−catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β−catenin and disrupt β−catenin/BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.
Disclosed are various embodiments for batched query processing and optimization in database management systems. A single algebraic expression is generated based at least in part on applying equivalence rules to algebraic expressions for a plurality of database queries of a database comprising a set of relations. The equivalence rules involve relational operators comprising Psi (Ψ) operators. The database can be queried using a single database query to create a result that is equivalent to the plurality of database queries.
One aspect described herein relates to a recombinant adeno-associated virus (rAAV) vector and a method for use thereof for treating Angelman Syndrome. Another aspect described herein is a UBE3A rAAV vector and method for use thereof for treating a UBE3A deficiency, e.g. Angelman syndrome, in humans.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
The present application is related to methods of treating traumatic brain injury in a subject in need thereof, by administering (a) pioglitazone, or a pharmaceutically acceptable salt thereof, and (b) mesenchymal stromal cells to the subject. Also disclosed herein are methods of treating one or more symptoms of traumatic brain injury in a subject in need thereof.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 9/00 - Medicinal preparations characterised by special physical form
91.
METHOD FOR DETECTION AND ANALYSIS OF CEREBROSPINAL FLUID ASSOCIATED UBE3A
A method and kit for diagnosing Angelman Syndrome by detecting and analyzing ubiquitination of the UBE3A protein in cerebrospinal fluid is presented. CSF is collected from a patient and incubated with a substrate, such as S5a, and ubiquitin. Ubiquitination of the substrate by UBE3A is measured and compared to a control sample for biochemical diagnosis of Angelman Syndrome. A method of determining the efficacy of a treatment is also presented in which CSF is collected from the patient both prior to and after treatment and incubated with a substrate and ubiquitin. Ubiquitination of the substrate by UBE3A is measured and an increase in ubiquitination in the sample obtained after treatment as compared to the reference sample collected prior to treatment indicates efficacy of the treatment.
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups
C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Clostridium difficileClostridioides difficileC. difficileC. difficileClostridium difficileClostridium difficile infection in a subject in need thereof by administering an amount of the engineered lysin-human defensin (LHD) protein(s) described herein.
C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
xyy; where M is a transition metal; wherein x is a number from about 1 to about 20; wherein y is a number from about 1 to about 20; wherein the shell component comprises a conducting polymer; and wherein the catalyst outer component is a transition metal that is not the same as the transition metal M. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Amyloids have been known to arise from many different proteins and polypeptides. These polypeptide chains generally form β-sheet structures that aggregate into long fibers; however, identical polypeptides can fold into multiple distinct amyloid conformations. The diversity of the conformations may have led to different forms of the prion diseases. In particular, large populations of small globular amyloid oligomers (gOs) and curvilinear fibrils (CFs) precede the formation of late-stage rigid fibrils (RFs), and have been implicated in amyloid toxicity. As disclosed herein, triarylmethane f dye crystal violet is a highly selective indicator of gOs and CFs. Therefore, disclosed herein are compositions, kits, and methods for detecting amyloids in a tissue, either in vitro or in vivo.
In one aspect, the disclosure relates to compositions of lithium cholesterol compositions, including, but not limited to, lithium cholesterol sulfate compositions which are useful as therapeutic agents. The disclosure also relates to methods of making lithium cholesterol compositions and pharmaceutical compositions comprising therapeutically effective amounts of the lithium cholesterol compositions. The present disclosure also includes compositions including lithium cholesterol compounds for use as a medicament and/or for use as in the treatment of one or more neurological conditions, such as, but not limited to Alzheimer's disease, autism spectrum disorder, bipolar disorder, or other neuropsychiatric disorders.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 25/00 - Drugs for disorders of the nervous system
Compounds, pharmaceutical compositions, and methods for treating tinnitus in a subject in need thereof. The methods include administering a therapeutically effective amount of a compound having a structure represented by Formula I as described herein. The compounds and compositions are administered transdermally or orally, preferably via a sustained release mechanism. The compounds and compositions reduce at least one behavioral correlate of tinnitus and/or at least one neurophysiological correlate of tinnitus. The compounds and compositions reduce hyperactivity in the auditory system.
C07C 257/18 - Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
98.
BIOMARKERS OF LOW GRADE GLIOMA AND PEDIATRIC NEUROBLASTOMA
The present disclosure relates to biomarkers and methods for determining or predicting survival of patients with low grade glioma (LGG) or pediatric neuroblastoma. Further disclosed are methods of diagnosing and treating patients with low grade glioma (LGG) or pediatric neuroblastoma.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
99.
LAYER-WISE CONTROL OF POST CONDENSATION FOR ADDITIVE MANUFACTURING
The disclosed subject matter relates to method for increasing the molecular weight of a polymer material during an additive manufacturing process. The method can comprise disposing a first layer of the polymer material at a target surface; exposing the first layer of the polymer material to an energy source for a sufficient period of time to sinter or melt and undergo a condensation reaction at least at a portion of the polymer material; controlling the condensation reaction to allow a desired increased number average molecular weight of the polymer material; and repeating the method steps to form an object in a layerwise fashion. Controlling the condensation reaction can comprise controlling and/or adjusting an energy 10 source-related parameter, a polymer-related parameter, a temperature related parameter, a vacuum related parameter, a process duration, a processing gas, an air flow volume and/or speed, or a combination thereof.
A system for forming a piling structure includes a hollow casing, a control assembly positioned proximately to the hollow casing, and a pivoting support device connected to the control assembly. A pivoting electrode is connected to the pivoting support device and configured to extend into the hollow casing. A second electrode is connected to the control assembly and extends into the hollow casing within the range of motion of the pivoting electrode. An electric power source is connected to the pivoting electrode and the second electrode, wherein charge on the electrodes produces a current arc between the pivoting electrode and the second electrode. A lift mechanism is positioned proximately to the hollow casing to control the electrodes position within the hollow casing.
patents
